International Journal of Radiation Research

en Performance of PSMA PET-CT imaging in predicting outcomes and assessing response in prostate cancer: a meta-analysis Radiation Biology Radiation Biology تحقيق بديع Original Research <div style="text-align: justify;">Background: One of the most widespread forms of cancer in males across the globe is prostate cancer (PC), which is seeing an upward trend in illness and death. The use of Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography (PSMA PET-CT) is gaining traction as a valuable imaging strategy that shows potential for diagnosing and monitoring PC. Nevertheless, existing studies on how PSMA PET-CT parameters influence patient outcomes show varying results, highlighting the need for definitive evidence to validate their predictive capabilities. Materials and Methods: The objective of this thorough examination and structured evaluation was to assess the predictive capacity of parameters derived from PSMA PET-CT in PC patients. The databases PubMed, EMBASE, Cochrane Library, and Web of Science were accessed to find research on the link between metrics generated from PSMA PET-CT and survival rates in PC patients. The meta-analysis utilized Stata version 14.0. To determine whether publication bias existed among the studies, Egger’s test was employed. Results: Seventeen research investigations that included 1,103 individuals were combined. The findings from the meta-analysis indicated that TV-PSMA emerged as a crucial factor in forecasting overall survival (OS) for PC patients (HR=1.69, 95% CI 1.24-2.29), while parameters related to SUV showed no meaningful association with OS or progression-free survival (PFS). Conclusion: The PSMA PET-CT-derived TV-PSMA parameters serve as reliable predictors of OS in PC patients, while SUV-related parameters and TL-PSMA each show no significant performance in prognostic predictions. Future research should seek to validate these findings in a broader population, and these parameters should be effectively incorporated into clinical decision-making to enhance patient outcomes.</div> Prostate cancer, prostate-specific membrane antigen, PET-CT, prognosis, meta-analysis. 665 675 http://ijrr.com/browse.php?a_code=A-10-1-1382&slc_lang=en&sid=1 S. Zhou 7900319475328460031682 7900319475328460031682 No The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China 310052 H. Ren 7900319475328460031683 7900319475328460031683 No The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China 310052 K. Zhu 7900319475328460031684 7900319475328460031684 No The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China 310052 S. Cheng slcheng@njmu.edu.cn 7900319475328460031685 7900319475328460031685 Yes Department of Gastroenterology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China 310052